Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Givlaari | givosiran | Acute hepatic porphyria (AHP) in adults | Reimburse with clinical criteria and/or conditions | Complete | ||
Glatect | Glatiramer acetate | Relapsing Remitting Multiple Sclerosis (RRMS) | Reimburse with clinical criteria and/or conditions | Complete | ||
Grastek | Phleum pratense | Allergic rhinitis | Do not list | Complete | ||
Grastofil | Filgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | ||
Gynazole.1 | Butoconazole nitrate | Vaginal infection | Do not list | Complete | ||
Halaven | Eribulin Mesylate | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Harvoni | Ledipasvir / Sofosbuvir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Harvoni | ledipasvir, sofosbuvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Hemangiol | Propranolol oral solution | Infantile hemangioma | Reimburse with clinical criteria and/or conditions | Complete | ||
Hemangiol | Propranolol | Infantile hemangioma | Withdrawn |